Your Sorted CME/CE Activities

Conversations in NASH: Updates from American Association for the Study of Liver Diseases*
Certified CME/CNE/CPE Activity
Non-alcoholic steatohepatitis (NASH) is a growing cause of cirrhosis, HCC, and liver transplantation. Treatment options for NASH remain limited. Management of NASH typically focuses on treating liver disease and associated metabolic comorbidities. However, no single treatment approach has proved universally applicable to the general population with NASH. Given the biologic complexity of NASH and its heterogeneity, it is unlikely that only one drug will be sufficient to treat all patients.

These educational Conversations in NASH will discuss the current and future burden of disease due to NASH, the potential noninvasive testing modalities for diagnosis and staging of disease, important management considerations, and the latest clinical data for the treatment of NASH.
Review the videos and claim AMA, ANCC or ACPE credit/contact hour(s) after completion of each brief Post-Test/Evaluation.





Ask the Expert
Naim Alkhouri, MD Naim Alkhouri, MD
Director of the Metabolic Liver Center
Texas Liver Institute
Associate Professor of Medicine
University of Texas San Antonio
Kris V. Kowdley MD Kris V. Kowdley MD, AGAF, FAASLD, FACG, FACP
Director, Liver Institute Northwest
Clinical Professor, Elson S. Floyd College of Medicine
Washington State University
       
Kirti Shetty, MD Kirti Shetty, MD
Professor of Medicine
Director of Hepatology and Liver Transplantation
University of Maryland School of Medicine
   

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2019 American Association for the Study of Liver Diseases annual meeting.
20
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
November 30, 2020
Mini Module
6582
ConversationsIn_WebBanner.NASH2(1150).gif
LiverDisease